Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

403
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
403
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

582
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
582
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

728
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
728
Hazard Ratio01:12

Hazard Ratio

740
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
740
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

221
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
221
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

398
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perisomatic innervation on the semilunar granule cells and outer molecular layer granule cells of the dentate gyrus of the mouse.

Frontiers in neuroanatomy·2026
Same author

Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?

PharmacoEconomics - open·2026
Same author

DNA damage and cell death induced by exposure to ultra-high dose rate low-dose pulsed X-rays emitted from a kilojoule plasma focus device.

Biological research·2026
Same author

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?

PharmacoEconomics - open·2026
Same author

Estimating the Clinical, Quality-of-Life and Economic Impact of Optimized Management of Type 2 Diabetes Patients in Spain.

Journal of clinical medicine·2026
Same author

The RELIANT checklist: a novel approach to revealing implicit factors in HTA deliberations.

Health policy OPEN·2025

Related Experiment Video

Updated: Apr 19, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.6K

Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies.

Carlos Crespo1, Antonio Monleon, Walter Díaz

  • 1Statistical Department, Facultat de Biologia, University of Barcelona, Avda Diagonal 645, 08028 Barcelona, Spain. ccrespo@ub.edu.

BMC Medical Research Methodology
|December 24, 2014
PubMed
Summary

A new meta-analysis method, Comparative Efficiency Research (COMER), was developed for cost-effectiveness studies. COMER is validated and useful for health decision-makers.

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.4K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.9K

Related Experiment Videos

Last Updated: Apr 19, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.6K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.4K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.9K

Area of Science:

  • Health Economics
  • Biostatistics
  • Meta-Analysis

Background:

  • Cost-effectiveness analysis is crucial for healthcare decision-making.
  • Existing meta-analysis methods may not adequately combine evidence from cost-effectiveness studies.
  • A novel approach is needed to synthesize findings from comparative efficiency research.

Purpose of the Study:

  • To develop and validate a new meta-analysis method for cost-effectiveness studies, termed Comparative Efficiency Research (COMER).
  • To introduce a new metric, total incremental net benefit (TINB), for assessing cost-effectiveness.
  • To evaluate the performance of COMER using copula distributions and simulated data.

Main Methods:

  • Developed TINB using inverse variance weighting of incremental net benefits (INB).
  • Utilized copula distributions to model the dependence between costs and quality-adjusted life years (QoL).
  • Validated the COMER method using a Spanish observational study and simulated cohorts across different cost-effectiveness scenarios.

Main Results:

  • The Frank copula demonstrated a good fit for modeling costs and QoL.
  • The TINB metric accurately predicted cost-effectiveness, with theoretical INB falling within the confidence intervals of TINB.
  • The TINB > 0 test showed significant results for cost-effective and dominant scenarios, even with small sample sizes.

Conclusions:

  • Comparative Efficiency Research (COMER) is a valid and reliable meta-analysis tool for cost-effectiveness studies.
  • The TINB metric provides a robust way to determine cost-effectiveness within a meta-analytic framework.
  • COMER can assist health decision-makers in synthesizing evidence from multiple cost-effectiveness studies.